Literature DB >> 20616500

Pituitary carcinomas.

Annamaria Colao, Arantzazu Sebastian Ochoa, Renata Simona Auriemma, Antongiulio Faggiano, Rosario Pivonello, Gaetano Lombardi.   

Abstract

Pituitary carcinoma is a extremely rare and is characterized by a very poor prognosis. Even if at diagnosis the presence of metastases is required to define a pituitary carcinoma, the lesion was almost invariably diagnosed first as a benign pituitary tumor, that after a variable period of latency, ranging from few months to many years, changed its natural course to an aggressive pituitary tumor poorly responsive to therapy. Recent studies have partially clarified its molecular pathogenesis and found possible markers of aggressiveness in order to make an earlier diagnosis, when still treatment could improve their prognosis. Most pituitary carcinomas are functioning, and ACTH- and PRL-secreting carcinomas are the most frequent. Treatment includes surgery, radiotherapy, medical therapy and chemotherapy, but the poor results with current therapies should prompt all investigators to better understand its pathogenesis and searching new molecular targets for treatments. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616500     DOI: 10.1159/000318499

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  12 in total

Review 1.  Medical treatment of prolactinomas.

Authors:  Annamaria Colao; Silvia Savastano
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 3.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

Review 4.  Genetically engineered mouse models of pituitary tumors.

Authors:  David A Cano; Alfonso Soto-Moreno; Alfonso Leal-Cerro
Journal:  Front Oncol       Date:  2014-08-01       Impact factor: 6.244

Review 5.  Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.

Authors:  Masaaki Yamamoto; Takahiro Nakao; Wataru Ogawa; Hidenori Fukuoka
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

Review 6.  Temozolomide in aggressive pituitary adenomas and carcinomas.

Authors:  Leon D Ortiz; Luis V Syro; Bernd W Scheithauer; Fabio Rotondo; Humberto Uribe; Camilo E Fadul; Eva Horvath; Kalman Kovacs
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

Review 7.  Advances in understanding pituitary tumors.

Authors:  Anna Kopczak; Ulrich Renner; Günter Karl Stalla
Journal:  F1000Prime Rep       Date:  2014-01-02

8.  Multiple intracranial and spinal metastases from a nonfunctioning pituitary adenoma following multiple surgeries: an illustrative case with 16 years of follow-up.

Authors:  Jun Wang; Er-Meng Ma; Peng-Fei Wu; Bo Qiu And; Yun-Jie Wang
Journal:  World J Surg Oncol       Date:  2014-12-12       Impact factor: 2.754

9.  Detection of circulating tumor cells in patients with pituitary tumors.

Authors:  Gao Hua; He Yanjiao; Liu Qian; Wang Jichao; Zhang Yazhuo
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430

10.  Prolactin Secreting Pituitary Carcinoma with Extracranial Spread Presenting with Pathological Fracture of Femur.

Authors:  Luis Rafael Moscote-Salazar; Guru Dutta Satyarthee; Willem Guillermo Calderon-Miranda; Jorge Aquino Matus; Alfonso Pacheco-Hernandez; Paulo Cesar Puac-Polanco; Amit Agrawal
Journal:  J Neurosci Rural Pract       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.